•  
  •  
 

Abstract

Background: Androgenic alopecia is characterized by its diffuse loss and the miniaturization of the hair. The study aimed to assess the safety and efficacy of procapil, redensyl, capixyl, bicapil, and anagain in topical hair growth serum in androgenic alopecia.

Methods: A prospective study was conducted on 110 healthy subjects aged 18-60 with androgenic alopecia in the Department of Dermatology, Tundla, Etmadhpur. Each subject applied 1 ml of serum on a dry scalp and was followed up on the 4th, 8th, 12th, and 16th week. Mean, median, and standard deviation were calculated. A repeated measure of the ANOVA test followed by post-hoc pairwise comparison using the Bonferroni test was applied. JAMOVI® (Sydney, Australia) software, was used for the statistical analysis.

Results: Seventy subjects completed the four follow-ups. Post hoc pair-wise comparison showed that each pair differed significantly, and an increased mean score was observed between the initial and follow-up assessments for the mean Anagen:Telogen (A:T) ratio and mean hair diameter [76.84 μm vs 77.77μm, 76.84μm vs 80.03 μm, 76.84 μm vs 82.33 μm; p<0.05]. A significant difference was found in hair density between baseline and 16th week [76.84 vs 84.60; p=0.002]. No adverse effects were observed.

Conclusion: This study's results suggest that after 120 days of treatment with hair serum, it is safe and effective, improving the A:T ratio, hair density, and hair thickness and hence reducing hair fall.

References

  1. Rambwawasvika H, Dzomba P, Gwatidzo L. Alopecia types, current and future treatment. J Dermat Cosmetol. 2021;5(4):93‒9.
  2. Zhou Y, Yu S, Zhao J, Feng X, Zhang M, Zhao Z. Effectiveness and safety of botulinum toxin type A in the treatment of androgenetic alopecia. Biomed Res Int. 2020:1–7
  3. Kanti V, Messenger A, Dobos GE, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
  4. Messenger A, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186–94.
  5. Bergfeld W, Washenik K, Callender V, et al. A phase III, multicenter, parallel-design clinical trial to compare the efficacy and safety of 5% minoxidil foam versus vehicle in women with female pattern hair loss. J Drugs Dermatol. 2016;15(7):874–81
  6. Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016; 82(2):128–34.
  7. Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): A systematic review. J Clin Aesthet Dermatol. 2016;9(7):56–62.
  8. Herz-Ruelas ME, Álvarez-Villalobos NA, Millán-Alanís JM, et al. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: A systematic review. Skin Appendage Disord. 2020;6(6):338–45.
  9. Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021;20(12):3759–81.
  10. Albuquerue TG, Castilho MC, Ramos F, Melo NR, Sanches-Silva A. A novel insight on an ancient aromatic plant: The rosemary (Rosmarinus officinalis L.). Trends Food Sci Tech. 2015;45(2):355–68.
  11. Panahi Y, Taghizadeh M, Marzony ET, Sahebkar A. Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: A randomized comparative trial. Skinmed. 2015;13(1):15–21.
  12. Hosking AM, Juhasz M, Mesinkovska NA. Complementary and alternative treatments for alopecia: A comprehensive review. Skin Appendage Disord. 2019;5(2):72–89.
  13. Eslahi E, Hashemi N, Shamaei S. Effectiveness of the active ingredients (Capixyl, Procapil, and rosemary extract) of the Trust® tonic for the treatment of androgenetic alopecia in comparison to minoxidil. Our Dermatol Online. 2022;13(4):346–51.
  14. Garre A, Piquero J, Trullas C, Martinez G. Efficacy and safety of a new topical hair loss-lotion containing oleanolic acid, apigenin, biotinyl tripeptide-1, diaminopyrimidine oxide, adenosine, biotin and ginkgo biloba in patients with androgenetic alopecia and telogen effluvium: A six-month open-label prospective clinical study. J Cosmo Trichol. 2018;4(1):1–6.
  15. Karaca N, Akpolat ND. A comparative study between topical 5% minoxidil and topical “redensyl, capixyl, and procapil” combination in men with androgenetic alopecia. J Cosmo Trichol. 2019;5(1):1–7.
  16. Trüeb RM. Serum biotin levels in women complaining of hair loss. Int J Trichology. 2016;8(2):73–7.
  17. Farris PK, Rogers N, McMichael A, Kogan S. A novel multi-targeting approach to treating hair loss, using standardized nutraceuticals. J Drugs Dermatol. 2017;16(11):141–8.
  18. Grothe T, Wandrey F, Schuerch C. Short communication: Clinical evaluation of pea sprout extract in the treatment of hair loss. Phytother Res. 2020;34(2):428–31.
  19. Kartal SP, Altunel C, Gencler B. Cosmetic procedures in the treatment of alopecia. Hair and Scalp Disorders. 2017:317–45.
  20. Kumar S, G R, K S. A study on the efficacy of microneedling with minoxidil solution versus microneedling with hair multivitamin solution for the treatment of androgenetic alopecia. Int J Dermatol Clin Res. 2023;14(8):104–7.
  21. Pillai JK, Mysore V. Role of low-level light therapy (LLLT) in androgenetic alopecia. J Cutan Aesthet Surg. 2021;14(4):385–91.
  22. Saed S, Ibrahim O, Bergfeld WF. Hair camouflage: A comprehensive review. Int J Womens Dermatol. 2017;3(1):75–80.
  23. Lalwala B, Das S, Srinivasa M, et al. Expert opinion on current and emerging treatment options in androgenetic alopecia and telogen effluvium: an Indian perspective. Int J Res Dermatol. 2022;8(1):152–60.
  24. Maramaldi G, Giacomelli L, Meneghin M, Eggenhoffner R, Togni S: Effectiveness of a multi-component lotion in the control of hair loss. Esper Dermatol. 2016;18(2):70–5.
  25. Katoulis AC, Liakou AI, Koumaki D, et al. A randomized, single-blinded, vehicle-controlled study of a topical active blend in the treatment of androgenetic alopecia. Dermatol Ther. 2020;33(4):e13734.
  26. Karaca N, Akpolat ND. A comparative study between topical 5% minoxidil and topical “redensyl, capixyl, and procapil” combination in men with androgenetic alopecia. J Cosmo Trichol. 2019;5(1):1–7.
  27. Kohli M, Ganjoo A, Sharma A, et al. Prospective efficacy and safety study of an innovative kerascalp hair growth serum in mild to moderate alopecia in India: Regrowth Study. Cureus. 2023;15(5):1–11.

Download

Share

COinS